Stem cell biotech, Advanced Cell Technology (ACT; stock symbol ACTC), has started off 2014 with indications that it is in a phase of rapid evolution. Some changes, such as today’s announced departure of now former CEO Gary Rabin (see my […]
Advanced Cell Technology (ACT) has confirmed that one of the patient in a clinical trial that it is running for treatment of macular degeneration, the leading cause of blindness worldwide, has shown a striking improvement in vision. The patient reportedly […]
One of the more exciting stem cell biotechs out there today is Advanced Cell Technology (ACT). At this time ACT has the only two ES cell-based FDA-approved clinical trials ongoing and so far they have looked quite promising in terms […]
Copyright © 2020 | Knoepfler Lab Stem Cell Blog, UC Davis, 1 Shields Ave, Davis, CA 95616. Designwork by Tradesouthwest Top
